Venrock Adviser, LLC
Filing Date
Global Rank
#1,000
/ 8,603
▲ 202
· as of Mar 2026
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
+29.2%
Period ended 3 months ago
Filed May 15, 2026 · 55d
25 quarters · since Mar 2020
Clone Performance
Jul 2023–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+238.7%
SPY
+76.0%
Annualised alpha
+29.4%
Max drawdown
−58.0%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
33 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
26.7%
−5.0 pts
Top 5
56.0%
+0.8 pts
Top 10
72.1%
−1.6 pts
HHI
1,038
Diversified−226
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $2,679,121,844 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc | +3,031,379 | 10,346,926 | $87,638,463 | |
| VOR | Vor Biopharma Inc. | +1,097,953 | 3,041,719 | $54,264,266 | |
| ZURA | Zura Bio Ltd | +1,089,875 | 6,434,990 | $38,288,190 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | +180,000 | 1,180,000 | $99,025,600 | |
| MAZE | Maze Therapeutics, Inc. | +53,465 | 1,602,034 | $47,820,714 | |
| HELP | Cybin Inc. | +11,404 | 3,851,654 | $18,487,939 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | −5,579,376 | 9,982,124 | $46,915,982 | |
| ELVN | Enliven Therapeutics, Inc. | −1,500,000 | 1,726,331 | $67,672,175 | |
| ERAS | Erasca, Inc. | −1,474,271 | 16,382,812 | $265,073,898 | |
| ORIC | Oric Pharmaceuticals, Inc. | −1,356,465 | 4,319,765 | $54,731,422 | |
| KALV | KalVista Pharmaceuticals, Inc. | −254,500 | 6,474,485 | $130,331,383 | |
| SEPN | Septerna, Inc. | −104,752 | 506,056 | $12,160,525 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
8 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | 3,603,595 | $93,333,110 | |
| RLMD | Relmada Therapeutics, Inc. | 4,843,380 | $33,709,924 | |
| TENX | Tenax Therapeutics, Inc. | 1,675,262 | $26,787,439 | |
| ANL | Adlai Nortye Ltd. | 3,212,731 | $22,232,098 | |
| IPSC | Century Therapeutics, Inc. | 8,695,652 | $19,652,173 | |
| KRRO | Korro Bio, Inc. | 1,009,500 | $11,427,540 | |
| ANRO | Alto Neuroscience, Inc. | 500,000 | $11,240,000 | |
| XFOR | X4 Pharmaceuticals, Inc | 330,525 | $1,365,068 | |
| No positions match the current search. | ||||
33 positions ·
$2,679,121,844 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| APGE |
Apogee Therapeutics, Inc.
Healthcare
|
Held | 8,493,321 | $714,882,828 | 26.68% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Reduced | 16,382,812 | $265,073,898 | 9.89% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 4,148,428 | $203,480,393 | 7.60% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Held | 3,685,448 | $185,893,997 | 6.94% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
Reduced | 6,474,485 | $130,331,383 | 4.86% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Added | 1,180,000 | $99,025,600 | 3.70% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
NEW | 3,603,595 | $93,333,110 | 3.48% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Added | 10,346,926 | $87,638,463 | 3.27% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 2,000,000 | $76,980,000 | 2.87% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Held | 3,882,709 | $75,945,788 | 2.83% | |
| SVRA |
Savara Inc
Healthcare
|
Held | 13,740,375 | $75,022,447 | 2.80% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 1,726,331 | $67,672,175 | 2.53% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
Reduced | 4,319,765 | $54,731,422 | 2.04% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Added | 3,041,719 | $54,264,266 | 2.03% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Added | 1,602,034 | $47,820,714 | 1.78% | |
| CTMX |
CytomX Therapeutics, Inc.
Healthcare
|
Reduced | 9,982,124 | $46,915,982 | 1.75% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Held | 3,220,364 | $45,246,114 | 1.69% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Held | 2,173,913 | $39,413,042 | 1.47% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,133,576 | $39,193,791 | 1.46% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Added | 6,434,990 | $38,288,190 | 1.43% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
NEW | 4,843,380 | $33,709,924 | 1.26% | |
| ENGN |
enGene Therapeutics Inc.
Healthcare
|
Held | 4,771,414 | $32,493,329 | 1.21% | |
| TENX |
Tenax Therapeutics, Inc.
Healthcare
|
NEW | 1,675,262 | $26,787,439 | 1.00% | |
| ANL |
Adlai Nortye Ltd.
Healthcare
|
NEW | 3,212,731 | $22,232,098 | 0.83% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
NEW | 8,695,652 | $19,652,173 | 0.73% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Held | 1,379,965 | $19,609,302 | 0.73% | |
| HELP |
Cybin Inc.
Healthcare
|
Added | 3,851,654 | $18,487,939 | 0.69% | |
| SRZN |
Surrozen, Inc./DE
Healthcare
|
Held | 632,931 | $18,437,280 | 0.69% | |
| SEPN |
Septerna, Inc.
Healthcare
|
Reduced | 506,056 | $12,160,525 | 0.45% | |
| KRRO |
Korro Bio, Inc.
Healthcare
|
NEW | 1,009,500 | $11,427,540 | 0.43% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
NEW | 500,000 | $11,240,000 | 0.42% | |
| ARTV |
Artiva Biotherapeutics, Inc.
Healthcare
|
Held | 1,609,569 | $10,365,624 | 0.39% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
NEW | 330,525 | $1,365,068 | 0.05% |